A Better Newspaper

## Overview Bundibugyo virus (BDBV), a species of Orthoebolavirus, is the subject of an ongoing outbreak in Africa described as a global public health concern, with no licensed medical countermeasures currently available (bioRxiv, August 10). ## Key Facts - The current BDBV outbreak in Africa is characterized as a global public health concern, particularly because there are no licensed medical countermeasures (MCM) (bioRxiv, August 10). - Researchers exposed 21 cynomolgus monkeys to BDBV to study disease progression and natural history, aiming to develop a well-characterized animal model to support MCM development (bioRxiv, August 10). - The study found BDBV disease (BVD) was more protracted in cynomolgus monkeys than reported for Ebola virus or Sudan virus infections, with a lower lethality rate of 67%, which is described as consistent with lower human BVD mortality rates (bioRxiv, August 10). - Immunohistochemistry and spatial proteomics identified CD209+ cells among other markers involved in disease pathogenesis (bioRxiv, August 10). ## Why It Matters This outbreak sits within a broader pattern of Ebola-family virus emergences in Central/East Africa (see also DRC Ebola outbreak coverage). The lack of licensed countermeasures specifically for BDBV — as opposed to Zaire ebolavirus, for which vaccines exist — creates urgency for animal model development and represents a gap in global pandemic preparedness that could affect public health policy, vaccine R&D funding, and international response coordination. ## Developments to Watch - Outbreak case counts and geographic spread in Africa. - WHO and international response coordination. - Progress on medical countermeasure development informed by animal model research. - Comparisons to other Orthoebolavirus species outbreaks (Sudan, Zaire).